Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.54 |
| ▸ | CTSK | P43235 | 15/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396123 | 0.95 | CTSS (0.50) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL16383457 | 0.90 | CTSS (0.52) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL29787460 | 0.88 | CTSS (0.53) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL14953746 | 0.86 | CTSS (0.54) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL31542573 | 0.86 | CTSS (0.42) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL19955305 | 0.86 | CTSK (0.72) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL10774431 | 0.86 | CTSK (0.72) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL30312625 | 0.86 | CTSS (0.52) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL30852949 | 0.85 | GLO1 (0.40) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5504395 | 0.85 | CTSS (0.53) | CTSSCTSKCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN, LTD. (TW) | 2023-12-21 | — | — | US | claimed |
| EP-4532531-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | ScinoPharm Taiwan, Ltd. (TW) | 2025-04-09 | — | — | EP | disclosed |
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN, LTD. (TW) | 2023-12-21 | — | — | US | disclosed |
| WO-2023234860-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN LTD. (TW) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | GLP1R, IAPP, GCG | CTSS 4337/4885CTSK 3191/4885CTSL 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.